Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | ($660.9K) | ($9,023.6K) | ($17.4M) | ($40.0M) | ($29.6M) | ($4,400.7K) | ($6,982.0K) | ($6,400.9K) | ($8,188.0K) | ($15.3M) | ($28.0M) | ($37.4M) | $20.2M | ($27.9M) | ($46.9M) | ($20.2M) | ($48.5M) | ($72.9M) | ($42.2M) | ($76.9M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Summit Therapeutics Inc.'s last 12-month Free Cash Flow is ($112.9M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Summit Therapeutics Inc.'s Free Cash Flow growth was 120.3%. The average annual Free Cash Flow growth rates for Summit Therapeutics Inc. have been 22.9% over the past three years, 29.7% over the past five years.
Over the last year, Summit Therapeutics Inc.'s Free Cash Flow growth was 120.3%, which is higher than industry growth of (0.1%). It indicates that Summit Therapeutics Inc.'s Free Cash Flow growth is Good.